CP and cancer: The combination of DOX-Hyd@AuNP efficiently transported and released the drug intracellularly into cancer cells, which led to reduction of mammosphere formation capacity and their cancer initiation activity, eliciting markedly improved tumor growth inhibition in murine models [198]; AuNPs prevented CP-induced acquired chemoresistance and stemness in ovarian cancer cells and sensitized them to CP [199].